Viva Biotech Holdings engages in the discovery, development, and manufacturing of clinical drugs. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2019-05-09. The firm has two segments. The Drug Discovery Services segment provides structure-based drug discovery services to biotech and pharmaceutical clients for preclinical innovative drug development. The Contract Design and Manufacturing (CDMO) and Commercialization Services segment is engaged in contract development and manufacturing services for small molecule Active Pharmaceutical Ingredients (APIs) and intermediates, as well as the trading of APIs, intermediates and finished products. The firm conducts business primarily in the United States, China, Europe and other regions.
Follow-Up Questions
Who is the CEO of VIVA Biotech Holdings?
Mr. Chen Cheney Mao is the Executive Chairman of the Board of VIVA Biotech Holdings, joining the firm since 2018.
What is the price performance of VBIZF stock?
The current price of VBIZF is $0.295, it has decreased 0% in the last trading day.
What are the primary business themes or industries for VIVA Biotech Holdings?
VIVA Biotech Holdings belongs to Life Sciences Tools & Services industry and the sector is Health Care
What is VIVA Biotech Holdings market cap?
VIVA Biotech Holdings's current market cap is $622.3M
Is VIVA Biotech Holdings a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for VIVA Biotech Holdings, including 3 strong buy, 3 buy, 1 hold, 0 sell, and 3 strong sell
